Shares of Adagio Therapeutics Inc (ADGI) are trading -3% lower at a price of $4.03 at the time of this writing. So far the Health Care sector has been having a somewhat gloomy day, and the share price of the company is far behind it's peers.


Adagio Therapeutics Inc has been trading between a 52-week high of $78.82 and a 52-week low of $2.41. The stock has a market cap of $439 Million.

Adagio (Nasdaq: ADGI) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company’s portfolio of antibodies has been optimized using Adimab’s industry-leading antibody engineering capabilities and is designed to provide patients and clinicians with a powerful combination of potency, breadth, durable protection (via half-life extension), manufacturability and affordability. Adagio’s portfolio of SARS-CoV-2 antibodies includes multiple, non-competing broadly neutralizing antibodies with distinct binding epitopes, led by ADG20.

Hedge Fund M28 Capital Increases Adagio Therapeutics (ADGI) Stake To 8.5%
ValueWalk 08-22-22

Adagio Therapeutics GAAP EPS of -$0.47
Seeking Alpha 08-15-22

Adagio Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
GlobeNewswire 08-15-22

Adagio Therapeutics Inc. (NASDAQ: ADGI): Is It Possible To Be Down -44.90% YTD And Still Lose Money
Marketing Sentinel 08-06-22

Adagio Therapeutics Inc. (NASDAQ: ADGI): Can A Stock Be Down -47.93% YTD, And Still Be A Loser
Marketing Sentinel 07-07-22